SSA
MREO

Schonfeld Strategic Advisors’s Mereo BioPharma MREO Stock Holding History

Schonfeld Strategic Advisors’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6,090,381
Closed -$2.54M – 2494
2025
Q4 		$2.54M Buy
6,090,381
+4,357,657
+251% +$8.29M 0.01% 790
2025
Q3 		$3.57M Buy
1,732,724
+823,084
+90% +$1.52M 0.02% 750
2025
Q2 		$2.47M Sell
909,640
-681,416
-43% -$1.64M 0.02% 868
2025
Q1 		$3.58M Buy
1,591,056
+1,097,156
+222% +$3.1M 0.02% 660
2024
Q4 		$1.73M Buy
+493,900
New +$1.94M 0.01% 891
2024
Q1 		– Sell
-50,100
Closed -$116K – 2280
2023
Q4 		$116K Sell
50,100
-80,500
-62% -$154K ﹤0.01% 1602
2023
Q3 		$168K Buy
130,600
+100
+0.1% +$133 ﹤0.01% 1445
2023
Q2 		$172K Sell
130,500
-30,100
-19% -$34.9K ﹤0.01% 1613
2023
Q1 		$114K Buy
160,600
+4,600
+3% +$4.14K ﹤0.01% 1669
2022
Q4 		$117K Buy
156,000
+4,600
+3% +$3.78K ﹤0.01% 2144
2022
Q3 		$130K Sell
151,400
-564,296
-79% -$690K ﹤0.01% 2485
2022
Q2 		$802K Sell
715,696
-163,427
-19% -$127K 0.01% 1120
2022
Q1 		$984K Buy
879,123
+158,330
+22% +$205K 0.01% 1000
2021
Q4 		$1.15M Sell
720,793
-100,000
-12% -$200K 0.01% 868
2021
Q3 		$1.99M Sell
820,793
-504,260
-38% -$1.34M 0.02% 718
2021
Q2 		$4.2M Buy
1,325,053
+52,000
+4% +$174K 0.04% 505
2021
Q1 		$4.29M Buy
1,273,053
+115,053
+10% +$407K 0.05% 466
2020
Q4 		$4.14M Buy
1,158,000
+814,805
+237% +$2.04M 0.06% 439
2020
Q3 		$899K Buy
+343,195
New +$1M 0.02% 727

Other funds holding MREO

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $712M AUM
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return

Schonfeld Strategic Advisors's MREO Position: Q1 2026 in Review

Schonfeld Strategic Advisors sold out of Mereo BioPharma (MREO) in Q1 2026, closing a stake of 6,090,381 shares — an estimated $2.54M sold.

Schonfeld Strategic Advisors first reported a position in MREO in Q3 2020 and held it in 19 quarters. The position peaked at $4.29M in Q1 2021. 63 funds tracked by Wall St. Rank hold MREO as of Q1 2026.

  • Schonfeld Strategic Advisors reported no remaining Mereo BioPharma position as of Q1 2026 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 6,090,381 Mereo BioPharma shares in Q1 2026, an estimated $2.54M.
  • Schonfeld Strategic Advisors first reported a position in Mereo BioPharma in Q3 2020 and held it in 19 quarters.
  • Schonfeld Strategic Advisors's Mereo BioPharma position peaked at $4.29M in Q1 2021.
  • 63 funds tracked by Wall St. Rank held Mereo BioPharma as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.